[go: up one dir, main page]

EA201071218A1 - Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью - Google Patents

Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью

Info

Publication number
EA201071218A1
EA201071218A1 EA201071218A EA201071218A EA201071218A1 EA 201071218 A1 EA201071218 A1 EA 201071218A1 EA 201071218 A EA201071218 A EA 201071218A EA 201071218 A EA201071218 A EA 201071218A EA 201071218 A1 EA201071218 A1 EA 201071218A1
Authority
EA
Eurasian Patent Office
Prior art keywords
active pharmaceutical
improved compositions
permeability
pharmaceutical components
bad permeability
Prior art date
Application number
EA201071218A
Other languages
English (en)
Other versions
EA032766B1 (ru
Inventor
Ян П. Мешвитцер
Алдо Кет
Хайке Динтерхайдорн
Original Assignee
Эбботт Продактс Гмбх
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Эбботт Продактс Гмбх filed Critical Эбботт Продактс Гмбх
Publication of EA201071218A1 publication Critical patent/EA201071218A1/ru
Publication of EA032766B1 publication Critical patent/EA032766B1/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/282Organic compounds, e.g. fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к пероральной фармацевтической лекарственной форме, которая содержит активный фармацевтический компонент с плохой проницаемостью и по меньшей мере одно вещество, улучшающее проницаемость, где вещество, улучшающее проницаемость, термостабильно встроено в водорастворимую матрицу из водорастворимого носителя, и к термостабильным составам, которые можно использовать для улучшения биодоступности.
EA201071218A 2008-04-22 2009-04-21 Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью EA032766B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08103657 2008-04-22
PCT/EP2009/054720 WO2009130204A2 (en) 2008-04-22 2009-04-21 Improved formulations for poorly permeable active pharmaceutical ingredients

Publications (2)

Publication Number Publication Date
EA201071218A1 true EA201071218A1 (ru) 2011-06-30
EA032766B1 EA032766B1 (ru) 2019-07-31

Family

ID=39816874

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201071218A EA032766B1 (ru) 2008-04-22 2009-04-21 Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью

Country Status (18)

Country Link
US (1) US20090263479A1 (ru)
EP (1) EP2268270A2 (ru)
JP (1) JP5726067B2 (ru)
KR (1) KR20110005883A (ru)
CN (1) CN102119025B (ru)
AR (1) AR071375A1 (ru)
AU (1) AU2009240050A1 (ru)
BR (1) BRPI0910758A2 (ru)
CA (1) CA2720658C (ru)
CO (1) CO6300932A2 (ru)
DO (1) DOP2010000318A (ru)
EA (1) EA032766B1 (ru)
EC (1) ECSP10010514A (ru)
IL (1) IL208370A0 (ru)
MX (1) MX2010011564A (ru)
NZ (1) NZ588369A (ru)
TW (1) TW200948399A (ru)
WO (1) WO2009130204A2 (ru)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto
WO2014048783A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
US9744240B2 (en) 2012-09-27 2017-08-29 Basf Se Storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin E-derivative and at least one hydrophilic polymer
US9789063B2 (en) 2012-09-27 2017-10-17 Basf Se Storage-stable dust-free homogeneous particulate formulation
WO2014048782A1 (en) 2012-09-27 2014-04-03 Basf Se A storage-stable dust-free homogeneous particulate formulation comprising at least one water-soluble vitamin e-derivative and at least one hydrophilic polymer
DK2953617T3 (da) * 2013-02-06 2020-01-20 Hermes Arzneimittel Gmbh Farmaceutiske sammensætninger, der inkorporerer lavdosislægemidler
RU2720680C2 (ru) 2014-06-18 2020-05-12 Ф. Хоффманн-Ля Рош Аг Новая фармацевтическая композиция, содержащая неионные сурфактанты
ES2829644T3 (es) 2014-06-20 2021-06-01 Hermes Arzneimittel Gmbh Composición farmacéutica oral de sabor enmascarado
CN111053755B (zh) * 2019-12-31 2022-03-29 金日制药(中国)有限公司 一种高渗透性的头孢克肟胶囊制剂制备方法
CN115209910A (zh) * 2020-03-18 2022-10-18 四川海思科制药有限公司 口服药物组合物
CN112704649A (zh) * 2020-12-30 2021-04-27 广东臻香荟生物科技有限公司 一种具备抑菌性能的香薰液
JP7368548B2 (ja) * 2021-07-02 2023-10-24 昊運股▲フン▼有限公司 薬学的組成物及びその使用
CN114601800B (zh) * 2021-09-28 2023-07-28 天津瑞普生物技术股份有限公司 一种甲磷丙泊酚钠无菌粉针剂及其制备方法
CN119677540A (zh) * 2022-03-04 2025-03-21 阿比泰克公司 用于基于脂质的药物递送系统的片剂剂型
WO2023174433A1 (en) * 2022-03-18 2023-09-21 Smart Pharmaceutical (Suzhou) Co., Ltd. Solid, semisolid, or liquid compositions for augmenting the stability, permeability and bioavailability of active pharmaceutical substances

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2921883A (en) * 1957-05-03 1960-01-19 Smith Kline French Lab Novel coating material for medicaments
US3145146A (en) * 1961-10-31 1964-08-18 Warner Lambert Pharmaceutical Modified mannitol for pharmaceutical tablets
US3477864A (en) * 1965-05-07 1969-11-11 Sumitomo Chemical Co Process for coating pharmaceutical preparations with a hydroxy propyl methyl cellulose-sealing agent moisture-preventing film
US3692543A (en) * 1971-01-28 1972-09-19 Wellman Lord Inc Food products
JPS57171428A (en) * 1981-04-13 1982-10-22 Sankyo Co Ltd Preparation of coated solid preparation
JPH085086B2 (ja) * 1992-07-14 1996-01-24 メリート株式会社 金型装置
DE19709532A1 (de) * 1997-03-10 1998-09-17 Basf Ag Verwendung von redispergierbaren Polymerpulvern oder Polymergranulaten zum Überziehen von pharmazeutischen oder agrochemischen Darreichungsformen
FR2790388B1 (fr) * 1999-03-04 2001-04-13 Synthelabo Compositions pharmaceutiques comprenant un benzamide et au moins un promoteur d'absorption
DE19913606A1 (de) * 1999-03-25 2000-09-28 Basf Ag Pulverförmige Solubilisationshilfsstoffe für feste pharmazeutische Darreichungsformen
DE10046541A1 (de) 2000-09-19 2002-03-28 Knoll Ag Mechanisch stabile darreichungsformen, enthaltend Ubichinone
US6692771B2 (en) 2001-02-23 2004-02-17 Cima Labs Inc. Emulsions as solid dosage forms for oral administration
KR100425226B1 (ko) * 2001-07-03 2004-03-30 주식회사 팜트리 아세클로페낙을 함유하는 경제적인 경구용 제제의 조성 및제법
AR038681A1 (es) * 2002-02-14 2005-01-26 Solvay Pharm Bv Formulacion oral de solucion solida de una sustancia activa pobremente soluble en agua
NZ535455A (en) * 2002-02-21 2009-08-28 Biovail Lab Int Srl Controlled release dosage forms
US6962006B2 (en) * 2002-12-19 2005-11-08 Acusphere, Inc. Methods and apparatus for making particles using spray dryer and in-line jet mill
WO2004062692A1 (en) * 2003-01-13 2004-07-29 Solvay Pharmaceuticals B.V. Formulation of poorly water-soluble active substances
SA04250283B1 (ar) * 2003-09-26 2008-05-26 سولفاي فارماسيتيكالز جي أم بي أتش مشتقات من amidomethy1-substituted1-(carboxyalkyl)-cyclopentylcarbonylamino-benzazepine-N-acetic acid
US7262184B2 (en) * 2003-09-26 2007-08-28 Solvay Pharmaceuticals Gmbh Amidomethyl-substituted 1-(carboxyalkyl) cyclopentyl-carbonylamino-benzazepine-N-acetic acid compounds, process and intermediate products for their preparation and pharmaceutical compositions containing them
US20070065513A1 (en) * 2003-10-31 2007-03-22 Avi Avramoff Stable lansoprazole formulation
ATE533473T1 (de) * 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma Neue klasse von surfuctantähnlichen materialien mit vitamin-e-tpgs und wasserlöslichem polymer
US20060240108A1 (en) * 2005-04-26 2006-10-26 Bernard Bobby L Cellulosic films incorporating a pharmaceutically acceptable plasticizer with enhanced wettability
FR2886293B1 (fr) * 2005-05-30 2007-08-24 Fournier S A Sa Lab Nouveaux composes de l'indoline
WO2006133733A1 (en) * 2005-06-13 2006-12-21 Flamel Technologies Oral dosage form comprising an antimisuse system
WO2007086078A2 (en) * 2006-01-30 2007-08-02 Panacea Biotec Ltd. Novel pharmaceutical compositions and process of preparation thereof
CA2641451C (en) * 2006-02-09 2012-10-02 Merck & Co., Inc. Polymer formulations of cetp inhibitors
EP2040731A4 (en) 2006-06-09 2010-05-19 Merrion Res Iii Ltd SOLID DOSAGE FORM FOR ORAL ADMINISTRATION CONTAINING AN ACTIVATOR
US7923026B2 (en) * 2006-10-20 2011-04-12 Solvay Pharmaceuticals B.V. Embedded micellar nanoparticles
CA2666587C (en) 2006-10-20 2015-12-22 Solvay Pharmaceuticals B.V. Micellar nanoparticles of chemical substances
US20070172525A1 (en) * 2007-03-15 2007-07-26 Ramesh Sesha Anti-diabetic combinations
AR071375A1 (es) 2008-04-22 2010-06-16 Solvay Pharm Gmbh Formulaciones para ingredientes farmaceuticos activos de permeabilidad deficiente, proceso de preparacion y producto

Also Published As

Publication number Publication date
CN102119025A (zh) 2011-07-06
WO2009130204A3 (en) 2010-08-05
EA032766B1 (ru) 2019-07-31
AR071375A1 (es) 2010-06-16
CA2720658C (en) 2016-07-12
CN102119025B (zh) 2014-09-03
CA2720658A1 (en) 2009-10-29
US20090263479A1 (en) 2009-10-22
JP5726067B2 (ja) 2015-05-27
BRPI0910758A2 (pt) 2018-03-20
JP2011518208A (ja) 2011-06-23
AU2009240050A1 (en) 2009-10-29
WO2009130204A2 (en) 2009-10-29
EP2268270A2 (en) 2011-01-05
MX2010011564A (es) 2011-03-02
ECSP10010514A (es) 2010-11-30
TW200948399A (en) 2009-12-01
DOP2010000318A (es) 2011-01-15
NZ588369A (en) 2012-06-29
CO6300932A2 (es) 2011-07-21
IL208370A0 (en) 2010-12-30
KR20110005883A (ko) 2011-01-19

Similar Documents

Publication Publication Date Title
EA201071218A1 (ru) Улучшенные композиции для активных фармацевтических компонентов с плохой проницаемостью
MY169461A (en) Pharmaceutical composition
TR200806298A2 (tr) Farmasötik formülasyon
UA107582C2 (uk) Таблетований препарат (4'-трифторметилфеніл)аміду (z)-2-ціано-гідроксибут-2-еноєвої кислоти з поліпшеною стійкістю
MX377553B (es) Composicion farmaceutica estable y metodos de uso de la misma.
EA200870599A1 (ru) Стабильные препараты лаквинимода
MX2010009851A (es) Oblea gingival.
EA201000089A1 (ru) Применение гомо- и сополимеров для стабилизации составов активных ингредиентов
EA201170289A1 (ru) Фармацевтические композиции и способы их получения при низкой концентрации примесей
EA200901365A1 (ru) Стабилизированная фармацевтическая композиция, содержащая прегабалин
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
UA109037C2 (ru) Триазолопиридины
EA201170512A1 (ru) Композиция для перорального введения
WO2009120389A8 (en) Oral and injectable formulations of tetracycline compounds
EA200801614A1 (ru) Фармацевтическая композиция, содержащая монтелукаст
TR201009394A2 (tr) Geliştirilmiş montelukast formülasyonları.
EA201071309A1 (ru) Твердая фармацевтическая композиция
TR200909785A1 (tr) Aktif ajan olarak sefdinir içeren farmasötik kompozisyonlar.
EA201390911A1 (ru) Фармацевтическая композиция, содержащая растительное действующее вещество
EA201100104A1 (ru) Фармацевтическая композиция, содержащая статин
EA201201329A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
EA201391369A1 (ru) Пероральные фармацевтические дисперсные композиции
EA201290250A1 (ru) Композиция, содержащая фезотеродин и балластные вещества
ECSP078024A (es) Inhibidores de la adenilato ciclasa soluble
EA201190243A1 (ru) Стабильная фармацевтическая композиция флударабина фосфата

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM